Two-year clinical outcomes of patients with long segments drug-eluting stents: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
Limited data are available on the long-term clinical efficacy of drug-eluting stent (DES) in diffuse long lesions. From May 2006 to May 2007, a total of 335 consecutive patients (374 lesions) were underwent percutaneous coronary intervention with implantation of long DES (≥ 30 mm) in real world practice. Eight-month angiographic outcomes and 2-yr clinical outcomes were compared between SES (n = 218) and PES (n = 117). Study endpoints were major adverse cardiac events including cardiac death, myocardial infarction, target-lesion revascularization, target-vessel revascularization and stent thrombosis. Baseline characteristics were similar in the two groups as were mean stent length (44.9 ± 15.2 mm in SES and 47.4 ± 15.9 in PES, P = 0.121). Late loss at 8 months follow-up was significantly lower in SES than in PES group (0.4 ± 0.6 mm in SES vs 0.7 ± 0.8 mm in PES, P = 0.007). Mean follow-up duration was 849 ± 256 days, and 2-yr cumulative major adverse cardiac events were significantly lower in the SES than in the PES group (5.5% in SES vs 15.4% in PES, P = 0.003). In conclusion, long-term DES use in diffuse long coronary lesions is associated with favorable results, with SES being more effective and safer than PES in this real-world clinical experience.
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Ung
U
Kim
Sang-Hee
SH
Lee
Geu-Ru
GR
Hong
Jong-Seon
JS
Park
Dong-Gu
DG
Shin
Young-Jo
YJ
Kim
Jae-Sik
JS
Jang
Tae-Hyun
TH
Yang
Dae-Kyeong
DK
Kim
Dong-Soo
DS
Kim
Dong-Kie
DK
Kim
Sang-Hoon
SH
Seol
Doo-Il
DI
Kim
Yoon-Kyung
YK
Cho
Hyung-Seop
HS
Kim
Chang-Wook
CW
Nam
Seung-Ho
SH
Hur
Kwon-Bae
KB
Kim
D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D017239:Paclitaxel; D020123:Sirolimus